

Your article submission 122237 External Inbox x

editorial@f1000research.com via amazonses.com Wed, May 25, 2022, 9:05 PM

Dear Eighty,

Records of Antibodies in Breast Milk after Getting a Vaccination and Suffered from COVID-19 in Postpartum Women: a Systematic Review
Mardiyani Kurniawati E and Rahmawati NA

Thank you for your submission to F1000Research. We noticed the following issue(s) with your article that must be resolved before continuing:

Plagiarism: We run plagiarism checks on all our submission to make sure that they are original (i.e. **have not been** published before) and are the authors' own work. Having run these checks, we noted that your manuscript has a degree of similarity to other sources, particularly in Tables 2 and 3.

Please re-word these sections before we undertake our pre-publication checks. We **have** attached the iThenticate report for further details on the plagiarised sections. We understand that it is harder to reword the methods section and, in these cases, we will be more lenient.

If applicable, please send a revised manuscript in response to this email.

Best regards,

Tabitha
The Editorial Team, F1000Research

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you **have** received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322926, Registered Office Howick Place, London SW1P 1WG, UK.

Please do not delete this e-mail. F1000 Research Ltd. 2022

eighty mardiyani kurniawati <eighty-m-k@fk.unsair.ac.id> Mon, May 30, 2022, 8:34 PM

Dear Editor

Thank you for the information regarding the article. We are currently revising our manuscript. We will send it to you immediately. Thank you for the opportunity.

Best regards

Eighty M.K

eighty mardiyani kurniawati <eighty-m-k@fk.unsair.ac.id> Thu, Jun 2, 2022, 9:16 AM

Dear Editor

We send our revised and paraphrased. Hope you are satisfied with our revision. We look forward to hearing from you soon regarding our manuscript. thank you

Best regards

Eighty M.K

One attachment • Scanned by Gmail

Records of Antibodies in Breast Milk after Getting a Vaccination and Suffered from COVID-19 in Postpartum Women: a Systematic Review

F1000.Research <research@f1000.com> to me [dropdown] Tue, Jun 7, 2022, 4:23 PM [star] [reply] [dropdown]

Dear Elghty,

Thank you for making these changes, we will continue with your submission and undertake our pre-publication checks. You should receive your revised article with our comments by the end of this week.

Best wishes,

Tabitha Lillywhite
Assistant Editor

[E Tabitha.Lillywhite@f1000.com](mailto:Tabitha.Lillywhite@f1000.com)

F1000
240 Blackfriars Rd
London SE1 8BF
www.f1000.com



Manuscript 122237 conditionally accepted for publication External [dropdown] Inbox x [dropdown] [print] [share]

editorial@f1000research.com via amazonise.com to me [dropdown] Wed, Jun 8, 2022, 5:49 PM [star] [reply] [dropdown]

Dear eighty

Records of Antibodies In Breast Milk after Getting a Vaccination and Suffered from COVID-19 In Postpartum Women: a Systematic Review
mardiyani kurniawati e and Rahmawati NA

Thank you for your submission to F1000Research. We **have** noted a few issues with your manuscript (below) – once these are addressed we will be pleased to accept your article for publication.

Research Resource Identifiers (RRIDs): We encourage you to add [RRIDs](#) in order to identify the following types of resources that are included in your article: software tools, data and databases. More information on this project is available from the Resource Identification Initiative and RRIDs can be obtained from the portal.

Gateways: I **have** included your article in the Emerging Diseases and Outbreaks gateway on F1000Research. Please confirm this inclusion.

Content: Heavy copyediting has **been** performed in order to improve the flow and readability of your article; please make sure the meaning has **been** maintained.

Reporting guidelines: We ask that authors include a completed PRISMA checklist with their article. This will come under the 'Reporting guidelines' heading in the *Data availability* section.

When completing the checklist, we would recommend indicating in which section/table/figure each item has **been** addressed rather than page number, as page numbers are likely to change during revisions and typesetting.

We ask that authors submit their checklist to an online repository. More information can be found on [our data guidelines page](#). Please create a public registry in order to create a DOI and assign a license to the data (we would strongly suggest a CC0 license). Please include the name of the repository, the project title and the DOI in the *Data availability* section, along with the license the data is held under.

Competing interests: Please disclose any competing interests the authors may **have**. If there are no competing interests, please state: 'No competing interests were disclosed'. More information can be found in our [policies](#).

Records of antibodies in breast milk in postpartum women who have t X [Active] SMART e

← [Icons] 67 of 76 < > [Icons]

e **eighty mardiyani kurniawati** <eighty-m-k@fk.unsir.ac.id> to F1000.Research
Fri, Jun 24, 2022, 7:33 AM ☆ ↶ ⋮

Dear Editor

Thank you for information regarding our manuscript. We **have** revised the point.

"The DOI you **have** provided for the PRISMA checklist does not resolve yet, please check that your dataset is public and that you **have** assigned an open license"
We **have** editing for public, you can access in https://datadryad.org/stash/share/GZ1PiaeeFKgD4uuhml14leFF0sVNUs3Zy2Q1eC_bo

"References must be cited in numerical order. Please revise the references, ensuring to update the in-text references and the reference list."
We **have** revised this part

"We **have** not yet received Figure 1, please provide Figure 1 as a separate file in either TIFF or JPEG format at >300dpi in response to this email."
We attach the file in this email

"Please confirm that you **have** obtained permission from the person you would like to acknowledge to be named in the manuscript."
We **have** permission from the person

Thank you

2 Attachments • Scanned by Gmail

Records of antibodies in breast milk in postpartum women who have t X [Active] SMART e

← [Icons] 67 of 76 < > [Icons]

F **F1000.Research** <research@f1000.com> to me
Fri, Jun 24, 2022, 6:44 PM ☆ ↶ ⋮

Dear Eighty,

Thank you for sending your revisions, we are currently setting your article up for production. However, we require that your dataset is public and that you **have** assigned an open license. A private view link is not acceptable. Could you ensure that your dataset on Dryad is public?

Information Classification: General

2

e **eighty mardiyani kurniawati** Dear Editor Thank you. We will try to fix this problem as soon as possible. Best regards Eighty M.K
Sat, Jun 25, 2022, 10:53 AM ☆

Your article 122237 is now accepted External Inbox

editorial@f1000research.com via amazonSES.com Fri, Jul 1, 2022, 11:29 PM to me

Dear eighty

Records of antibodies in breast milk in postpartum women who have been vaccinated or exposed to COVID-19: A systematic review mardiyani Kurniawati E and Rahmawati NA

We have now accepted your article for publication in F1000Research. It will be sent to the typesetters and a member of the Production team will send you a proof in due course.

Please note that your article will only be published once you have suggested 5 suitable reviewers who meet our reviewer criteria. Please do not contact your suggested reviewers, as this has the potential to influence and invalidate their review. Our editorial team will contact any suitable reviewers on your behalf, and will be your main contact once your article has been published.

Best wishes,

Tabitha The Editorial Team, F1000Research

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office: Howick Place, London SW1P 1WS, UK.

Do not delete (filing code): F1KR00CDE.F1R-VER134202-A (end code)